Home Biosimilar Antibodies Immunology & Inflammation IFN Emapalumab (anti-IFNγ) For research use only.
Not for use in humans.

Emapalumab (anti-IFNγ)

Synonyms: Gamifant

Emapalumab (anti-IFNγ), a monoclonal antibody directed against IFNγ, is the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory.

Emapalumab (anti-IFNγ)

Purity & Quality Control

Batch: Purity: 99% Protein concentration: 9.24mg/ml Endotoxin Level: ＜1EU/mg
99

Choose Selective IFN Inhibitors

Biological Activity

Description Emapalumab (anti-IFNγ), a monoclonal antibody directed against IFNγ, is the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory.

Product Details

CAS No. 1709815-23-5
Molecular Weight 135 KD
Isotype Human IgG1
Application Emapalumab (anti-IFNγ)
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Emapalumab (anti-IFNγ) | Emapalumab (anti-IFNγ) supplier | purchase Emapalumab (anti-IFNγ) | Emapalumab (anti-IFNγ) cost | Emapalumab (anti-IFNγ) manufacturer | order Emapalumab (anti-IFNγ) | Emapalumab (anti-IFNγ) distributor